argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

October 24, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Tuesday, October 31, 2023 at 1:30 pm CET (8:30 am ET) to discuss its third quarter 2023 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

Belgium                32 800 50 201France                        33 800 943355Netherlands                31 20 795 1090United Kingdom        44 800 358 0970United States                 1 888 415 4250Japan                        81 3 4578 9081Switzerland                41 43 210 11 32

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:

Erin [e-mail]

Investors:

Alexandra Roy (US)[e-mail]

Lynn Elton (EU)[e-mail]